ORIC News

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seekingalpha | 1 month ago

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript

Seekingalpha | 3 months ago

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of “Moderate Buy” from Analysts

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation

Defenseworld | 4 months ago

After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright

From a technical perspective, Oric Pharmaceuticals, Inc. (ORIC) is looking like an interesting pick, as it just reached a key level of support. ORIC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Zacks | 4 months ago

Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade

The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 58.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 4 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Seekingalpha | 5 months ago

ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside

ORIC Pharmaceuticals is advancing two best-in-class small molecule inhibitors targeting resistance mechanisms in prostate and lung cancer. ORIC's $413 million cash position, bolstered by a 2025 equity raise, secures operations and Phase 3 trial funding into the second half of 2028. Rinzimetostat and enozertinib have shown promising efficacy and safety in early trials, with both candidates entering registrational Phase 3 studies by 2026.

Seekingalpha | 6 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript

Seekingalpha | 7 months ago

Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know

Oric Pharmaceuticals (ORIC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 8 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC ) Pharmaceuticals, Inc. Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants Jacob Chacko - President, CEO & Director Dominic Piscitelli - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Welcome back everyone. This is final session of the second day of the Biopharma Back to School Summit.

Seekingalpha | 10 months ago

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

From a technical perspective, Oric Pharmaceuticals, Inc. (ORIC) is looking like an interesting pick, as it just reached a key level of support. ORIC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Zacks | 1 year ago

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago

Oric Pharmaceuticals Inc. (ORIC)